Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dystroglycan is frequently lost in adenocarcinoma, but the mechanisms and consequences are poorly understood. We report an analysis of β-dystroglycan in prostate cancer in human tissue samples and in LNCaP cells in vitro. There is progressive loss of β-dystroglycan immunoreactivity from basal and lateral surfaces of prostate epithelia which correlates significantly with increasing Gleason grade. In about half of matched bone metastases there is significant dystroglycan re-expression. In tumour tissue and in LNCaP cells there is also a tyrosine phosphorylation-dependent translocation of β-dystroglycan to the nucleus. Analysis of gene expression data by microarray, reveals that nuclear targeting of β-dystroglycan in LNCaP cells alters the transcription of relatively few genes, the most unregulated being the transcription factor ETV1. These data suggest that proteolysis, tyrosine phosphorylation and translocation of dystroglycan to the nucleus resulting in altered gene transcription could be important mechanisms in the progression of prostate cancer.

Original publication

DOI

10.1038/srep02792

Type

Journal article

Journal

Sci Rep

Publication Date

30/09/2013

Volume

3

Keywords

Androgens, Cell Line, Tumor, Cell Nucleus, Dystroglycans, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Male, Myristic Acid, Oligonucleotide Array Sequence Analysis, Phosphorylation, Phosphotyrosine, Prostate, Prostatic Neoplasms, Protein Transport, Transcription Factors, Transcription, Genetic